Skip to main content
Premium Trial:

Request an Annual Quote

Michael Stapleton, Joseph Mollica, Hanne Dannulat, David Muth


Michael Stapleton has resigned as COO of Accelrys, the software division of Pharmacopeia. He will stay with the company until December 31, 2002. Until a replacement is hired, Joseph Mollica, CEO of Pharmacopeia, will serve as acting COO of Accelrys. The company did not provide further details on Stapleton’s departure.

Hanne Dannulat has joined San Diego-based Structural Bioinformatics as European managing director. Dannulat most recently held positions in the areas of sales, sales management, marketing, new product launches, and strategic planning with Glaxo Wellcome and GlaxoSmith-Kline. She will be responsible for planning and management of SBI’s European commercial operation and will report directly to David Muth, president and COO.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.